Clinical trials: Sepsis Septic Shock
Septic Shock
Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- NCT04884854
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Efferon JSC
Sepsis, Septic Shock
Predictive algoRithm for EValuation and Intervention in SEpsis
In this prospective study, the ability of a machine learning algorithm to predict sepsis and influence clinical outcomes, will be investigated at Cabell Huntington Hospital (CHH).
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- PREVISE (NCT03235193)
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 2,296 people
- Sponsor
- Dascena
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem
Septic Shock
Lipopolysaccharide Adsorption At Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- LASSO (NCT04827407)
- Testing
- Efferon LPS hemoperfusion
- Where
- 4 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Efferon JSC
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
VENUS: Septic Gene Expression Using SeptiCyte
The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their…
- Trial name
- VENUS (NCT02127502)
- Where
- 6 sites in United States
- Volunteers
- 379 people
- Sponsor
- Immunexpress
Septic Shock
A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock
To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.
- Trial name
- PROCYSS (NCT04963920)
- Testing
- Cytosorb® 300 ml
- Where
- 18 sites in Germany
- Volunteers
- 260 people
- Sponsor
- CytoSorbents Europe GmbH
Inpatient Hospitalization, Intensive Care Unit Admission, Inpatient Mortality, Sepsis and Septic Shock
Linking Novel Diagnostics With Data-Driven Clinical Decision Support in the Emergency Department
The primary objective of this study is to validate the use of an electronic clinical decision support (CDS) tool, TriageGO with Monocyte Distribution Width (TriageGO-MDW), in the emergency department (ED).
- Trial name
- NCT05335135
- Testing
- TriageGO-MDW Clinical Decision Support, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Stocastic, LLC
Septic Shock, Sepsis
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
- Conditions
- Septic Shock, Sepsis, Hypovolemia
- Trial name
- VBI-S-02 (NCT06072430)
- Testing
- VBI-S
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Vivacelle Bio
Sepsis, Hypotension
Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
This study assesses the mean difference in fluid balance at ICU discharge and associated patient outcomes, based on a dynamic assessment of fluid responsiveness in septic patients with refractory hypotension in an ICU setting.
- Trial name
- FRESH (NCT02837731)
- Testing
- Treatment Starling SV monitor
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cheetah Medical Inc.
Sepsis, Septic Shock
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock
Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications and clinical studies on the topic of Sepsis and septic shock on the National Library of Medicine resource The National Center for…
- Trial name
- NCT06404424
- Testing
- Efferon LPS, Efferon CT
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- Efferon JSC
Sepsis, Severe Sepsis
Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study
The primary objective is to demonstrate that the plasma inducible nitric oxide synthase (iNOS) assay (PliNOSa® test) has an acceptable relative risk ratio for predicting the onset of sepsis within 72 hours of testing when…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- PliNOSa® Test (NCT01371929)
- Volunteers
- 166 people
- Sponsor
- Research & Diagnostic Antibodies
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Severe Sepsis With Septic Shock
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7B (Immune…
- Trial name
- IRIS-7-B (NCT02640807)
- Testing
- Interleukin-7
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revimmune
Septic Shock
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
The primary objective of this clinical investigation is to investigate the feasibility and possible benefits of the Alteco® LPS Adsorber in treating patients with septic shock with presumed endotoxemia of abdominal or urogenital…
- Trial name
- ASSET (NCT02335723)
- Testing
- Alteco LPS Adsorber
- Where
- 6 sites in Finland, Norway and 1 more
- Volunteers
- 15 people
- Sponsor
- Alteco Medical AB
Septic Shock
First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression
The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.
- Trial name
- RESTORE I (NCT06258291)
- Testing
- Hemosystem REBOOT
- Where
- 2 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- hemotune AG
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic…
- Trial name
- SYMON II (NCT06654895)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- Bluejay Diagnostics, Inc.
Healthy Subjects
A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229
This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered…
- Trial name
- NCT07285603
- Testing
- M6229
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Matisse Pharmaceuticals
Sepsis, Septic Shock
An Algorithm Driven Sepsis Prediction Biomarker
A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated.
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- NCT03015454
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Dascena
Sepsis, Acute Infection
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.
- Trial name
- NCT06665542
- Where
- 8 sites in United States, Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Severe Sepsis, Septic Shock
Procalcitonin Monitoring Sepsis Study
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
- Trial name
- MOSES (NCT01523717)
- Where
- 13 sites in United States
- Volunteers
- 858 people
- Sponsor
- Brahms AG